Elanco Animal Health Incorporated (ELAN)
Elanco Animal Health: New Products To Support Growth
I recommend a buy rating for Elanco Animal Health, driven by a strong new product cycle and robust clinic adoption. Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth and margin expansion for ELAN. Befrena offers another growth lever, with early demand exceeding expectations, though near-term contribution is limited by supply constraints.
Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform
Elanco Animal Health is transitioning from a leveraged consolidator to an innovative competitor, with new products driving EBITDA growth and market share gains. ELAN's innovation portfolio, including Zenrelia, Credelio Quattro, and Befrena, is capturing share in dermatology and parasiticide markets, challenging Zoetis' key franchises. Margin expansion and deleveraging are underway, supported by the Ascend program and strong cash flow; net leverage is targeted below 3.0x by 2027.
Elanco Animal Health Q2 Earnings Call Highlights
Elanco Animal Health NYSE: ELAN reported second-quarter 2026 revenue of $1.368 billion, up 10% on a reported basis and 8% organically in constant currency, as demand for new pet-health products and strength in U.S. farm animal operations supported growth.
Elanco Animal Health (ELAN) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Beat Estimates
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.26 per share a year ago.
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: Should You Buy?
Elanco Animal Health (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You Looking for a Top Momentum Pick? Why Elanco Animal Health Incorporated (ELAN) is a Great Choice
Does Elanco Animal Health Incorporated (ELAN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is the Options Market Predicting a Spike in Elanco Animal Health Stock?
Investors need to pay close attention to ELAN stock based on the movements in the options market lately.
Elanco Animal Health Incorporated (ELAN) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Elanco Animal Health Incorporated (ELAN) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript
Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript
Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.4 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.37 per share a year ago.
